SYDNEY, Dec. 11, 2012 /CNW/ - http://www.sirtex.com informs doctors, patients and investors about the world's most widely used and widely studied form of SIRT for all ...
Sirtex Completes Patient Recruitment for SIRFLOX Study Evaluating SIR-Spheres® Microspheres as First
World's Largest Interventional Oncology Study with More Than 500 Patients Enrolled WOBURN, Mass.--(BUSINESS WIRE)-- Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative ...
Study results for patients with Hepatocellular Carcinoma presented at International Liver Cancer Association Virtual Conference WOBURN, Massachusetts, Sept. 14, 2020 /PRNewswire/ -- Sirtex Medical ...
Sirtex brings an innovative liver cancer treatment delivery system to Europe, enhancing options for physicians and their patients. WOBURN, Mass., Sept. 16, 2024 /PRNewswire/ -- Sirtex Medical ("Sirtex ...
WOBURN, Massachusetts, June 24, 2019 /PRNewswire/ -- Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of SIR-Spheres® Y ...
Broadened indication increases access to liver cancer treatment across Europe and CE-marked territories. "This milestone is about more than regulatory approval—it's about giving hope and options back ...
WOBURN, Mass., Nov. 25, 2020 /CNW/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that Sirtex with the support of its shareholder, China Grand ...
PHILADELPHIA, May 8 (UPI) -- Sirtex said Monday it would launch a study to test the use of its SIR-Spheres Microspheres with Xeloda for liver cancer. Sirtex said its product is the only radioactive ...
Physicians and employees recognized for their role in this milestone and impact made on patient lives WOBURN, Massachusetts, June 24, 2019 /PRNewswire/ -- Sirtex Medical, a leading manufacturer of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results